- Home
- PRME vs IGR Comparison
PRME vs IGR Comparison
Compare PRME & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- IGR
- Stock Information
- Founded
- PRME 2019
- IGR 2004
- Country
- PRME United States
- IGR United States
- Employees
- PRME N/A
- IGR N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- IGR Finance Companies
- Sector
- PRME Health Care
- IGR Finance
- Exchange
- PRME Nasdaq
- IGR Nasdaq
- Market Cap
- PRME 601.1M
- IGR 776.6M
- IPO Year
- PRME 2022
- IGR N/A
- Fundamental
- Price
- PRME $3.41
- IGR $4.80
- Analyst Decision
- PRME Buy
- IGR
- Analyst Count
- PRME 6
- IGR 0
- Target Price
- PRME $9.31
- IGR N/A
- AVG Volume (30 Days)
- PRME 3.8M
- IGR 747.7K
- Earning Date
- PRME 11-07-2025
- IGR 01-01-0001
- Dividend Yield
- PRME N/A
- IGR 13.93%
- EPS Growth
- PRME N/A
- IGR N/A
- EPS
- PRME N/A
- IGR N/A
- Revenue
- PRME $5,977,000.00
- IGR N/A
- Revenue This Year
- PRME $179.58
- IGR N/A
- Revenue Next Year
- PRME N/A
- IGR N/A
- P/E Ratio
- PRME N/A
- IGR N/A
- Revenue Growth
- PRME 647.13
- IGR N/A
- 52 Week Low
- PRME $1.11
- IGR $3.88
- 52 Week High
- PRME $6.94
- IGR $5.70
- Technical
- Relative Strength Index (RSI)
- PRME 35.80
- IGR 38.59
- Support Level
- PRME $3.45
- IGR $4.82
- Resistance Level
- PRME $4.00
- IGR $4.90
- Average True Range (ATR)
- PRME 0.41
- IGR 0.08
- MACD
- PRME -0.15
- IGR -0.00
- Stochastic Oscillator
- PRME 11.14
- IGR 5.96
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.